Progressive dose escalation from 0.5mg (40-60y) to 3mg (70-80y) compensates for age-related pineal melatonin output decline (50-75% between ages 40-70) in AD prevention. This addresses the biological reality of declining melatonin with age while providing proportional receptor activation across the lifespan. However, the causal relationship between melatonin decline and AD risk remains unproven—decline may be epiphenomenal rather than causal. Age-related receptor changes (density, coupling efficiency) are not addressed by hormone replacement alone. Requires biomarker validation and large prevention trial.
Curated pathway from expert analysis
flowchart TD A["Aging 40-70 years"] -->|"reduced activity"| B["AANAT and ASMT decline"] A -->|"50-75% output loss"| C["Pineal melatonin decline"] B -->|"enzyme insufficiency"| C C -->|"insufficient ligand"| D["MT1/MT2 receptor activation decreased"] D -->|"downstream signaling loss"| E["Neuroprotective signaling impaired"] E -->|"chronic pathway disruption"| F["Alzheimer risk elevated"] F -->|"biomarker changes"| G["Age-stratified dosing signal"]
No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for AANAT; yet. Search RCSB →
Median TPM across 13 brain regions for AANAT; ASMT; MT1/MT2 from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for AANAT; ASMT; MT1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If age-stratified melatonin replacement dosing (higher doses in older subjects to compensate for greater AANAT/ASMT decline) improves sleep quality and reduces neurodegeneration biomarkers, then age-s | In adults >65 (n≥80), age-stratified melatonin (0.5mg at 65-75y, 1mg at >75y) vs fixed 0.3mg dose, over 12 months: greater sleep efficiency improvement (>15% vs | — no observation — | pending | 0.70 |